Marksans Pharma announced that UK MHRA has granted MarketAuthorisation to the Company's wholly owned subsidiary Relonchem Limited for Fluoxetine 20mg/5ml Oral Solution.

Therapeutic use of the product is for treatment of depressive illness and other mental/mood disorders.

The product will be manufactured at the plant of Bell, Sons & Co. (Druggists) located at Gifford House, Slaidburn Crescent, Southport, UK.

Powered by Capital Market - Live News

The drug maker said that the therapeutic use of the product is for treatment of depressive illness and other mental/mood disorders.

The product will be manufactured at the plant of Bell, Sons & Co. (Druggists) Ltd. located at Gifford House, Slaidburn Crescent, Southport, UK.

Mumbai-based Marksans Pharma is engaged in the research, manufacturing & marketing of generic pharmaceutical formulations in the global markets.

The drug maker consolidated net profit rose 29.9% to Rs 60.12 crore on a 25.3% increase in revenue from operations to Rs 452.56 crore in Q2 FY23 over Q2 FY22.

The scrip fell 1.41% to currently trade at Rs 66.20 on the BSE.

Powered by Capital Market - Live News

Marksans Pharma raised Rs. 372.40 crore through the conversion of warrants into equity shares by OrbiMed Asia IV Mauritius FVCI, and Mark Saldanha (promoter of the company).

OrbiMed is a global healthcare investment firm with over $18 billion in assets under management. The warrants are converted at a price of Rs 74 per share.

The convertible warrants were issued to OrbiMed and the promoter of the company on 23 July 2021, at a price of Rs 74 per warrant. The company received Rs. 93.09 crore in July 2021 and with the conversion, the balance amount of Rs 279.29 crore have also been received by the company in January 2023. OrbiMed Asia IV Mauritius FVCILimited will own a 10.88% stake in the company and the promoter stake will be 43.80%.

OrbiMed's exercise of warrant conversion will further strengthen the company's net cash position to over Rs 650 crore.

Commenting on the fundraise, Mark Saldanha, managing director of the company said We thank OrbiMed for believing in Marksans and supporting us in our growth journey to become a global pharmaceutical company. Our strotegic partnership will be bolstered through OrbiMed's deep global healthcare experience. The warrant conversion has augmented our already strong balance sheet. Marksans is now well-positioned to execute the next leg of growth.

Marksans strives to generate cantinuous shareholder returns by incorporating best governance practices and OrbiMed's can version underpins our endeavour. We continue to value the expertise of Dr. Sunny Sharma on Marksans Board.

Commenting on the conversion, Dr. Sunny Sharma, senior managing director of OrbiMed Asia said Marksans Pharma has built a strong global private label and own-brand OTe business. Mark and the management team have delivered robust growth over the past few years. We look forward to continued execution on the company's differentiated business model.

Mumbai-based Marksans Pharma is engaged in the research, manufacturing & marketing of generic pharmaceutical formulations in the global markets.

Marksans Pharma's consolidated net profit rose 29.9% to Rs 60.12 crore on a 25.3% increase in revenue from operations to Rs 452.56 crore in Q2 FY23 over Q2 FY22.

Powered by Capital Market - Live News

The Board of Marksans Pharma at its meeting held on 20 January 2023 has allotted 5,03,24,324 equity shares on conversion of warrants issued on preferential basis.

Accordingly, the paid up equity share capital of the company has increased to Rs 45,31,63,746 dividend into 45,31,63,746 equity shares of Re 1 each with effect from 20 January 2023.

Powered by Capital Market - Live News